Eli Lilly has signed a deal worth up to $2.75 billion with Hong Kong-based Insilico Medicine to license and commercialize AI-discovered oral therapeutics worldwide. Lilly will pay $115 million upfront, with the remainder tied to development, regulatory, and commercial milestones plus royalties on future sales.
Insilico's Pharma.AI platform uses generative AI and deep learning to identify disease targets and design drug molecules from scratch. The company has developed at least 28 drug candidates using AI, with nearly half already in clinical trials. CEO Alex Zhavoronkov called Lilly "the absolutely best partner" and said the company aims to develop the next breakthrough after tirzepatide (Mounjaro).
The deal is one of the largest AI-driven drug discovery agreements ever signed and signals major pharma's growing confidence in computational drug design. Lilly VP Andrew Adams said Insilico's AI capabilities "represent a powerful complement to Lilly's deep expertise in clinical development."
